This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BiOasis Announces Completion Of Mass Spectrometry Method Intended To Assist With In Vitro Diagnosis Of Alzheimer's Disease

VANCOUVER, British Columbia, Dec. 13, 2010 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) announced today the completion of the development and initial testing of a second method to detect levels of a serum protein (p97) that is reported to be associated with Alzheimer's disease (AD). The project, which was initiated and announced in late 2008, was intended to develop a SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) assay capable of detecting and measuring protein levels in human plasma.

SISCAPA is a new proprietary technique that was developed to measure the levels of proteins in human plasma and is based on immunoaffinity enrichment of peptide surrogates of biomarker proteins and their identification by mass spectrometry. The technique offers excellent analytical performance featuring robustness to sample degradation and common interferences such as autoantibodies that may be seen in biological fluids.

The SISCAPA assay for p97 was developed for biOasis by the Anderson Forchung Group of Washington DC. AFG is a privately held company working to advance technologies for biomarker measurement, with a focus on proteins useful in clinical diagnostics. "The SISCAPA assay has demonstrated the ability to reliably detect p97 in plasma, and will assist biOasis with providing unique and valuable diagnostic tools" said Leigh Anderson, AFG's chief executive officer.

"We are extremely lucky to have a close relationship with the Anderson Forchung Group. They are the inventors of the SISCAPA technique and the founder of AFG, Dr. Leigh Anderson, is an advisor to biOasis," says Rob Hutchison CEO. "The Company intends to use the SISCAPA assay within the Cognitest™ development program, and is exploring additional commercial opportunities for the method."

ABOUT COGNITEST™

biOasis is developing a proprietary blood test for the diagnosis of Alzheimer's disease - Cognitest™. Current initiatives within the Cognitest™ program include product and method development, validation using human samples, and regulatory approval in Europe. To enable faster adoption and greater use of Cognitest™ the Company intends to out license it to multiple corporate partners.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs